Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.39 |
| ▸ | HPGD | P15428 | 6/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30963678 | 0.75 | BRPF1 (0.44) | KDM4EHPGDBRPF1ALDH1A1HSD17B10 | |
| SCHEMBL2731241 | 0.75 | BRPF1 (0.44) | KDM4EHPGDBRPF1ALDH1A1HSD17B10 | |
| SCHEMBL15231171 | 0.74 | — | — | |
| SCHEMBL15515362 | 0.73 | CA12 (0.46) | BRPF1CA12CA9HTR2B | |
| SCHEMBL13158906 | 0.70 | BRPF1 (0.66) | KDM4EHPGDBRPF1ALDH1A1HSD17B10 | |
| SCHEMBL5739134 | 0.68 | SIRT6 (0.34) | — | |
| SCHEMBL68595 | 0.68 | CA12 (0.45) | KDM4EHPGDBRPF1ALDH1A1HSD17B10 | |
| SCHEMBL26604953 | 0.67 | PKM (0.42) | KDM4EHPGDALDH1A1HSD17B10GAA | |
| Hydrochloric Acid SCHEMBL2034214 | 0.66 | CA12 (0.43) | KDM4EHPGDBRPF1ALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL10863156 | 0.66 | CA12 (0.43) | KDM4EHPGDBRPF1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372528-A1 | GLYCOCONJUGATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2023-11-23 | — | — | US | disclosed |
| US-8063038-B2 | vasopressin V2 receptor agonists for treating nocturnal enuresis, nocturia, diabetes insipidus, urinary incontinence and bleeding disorders; {1-[4-(5H,11H-Benzo[e]pyrrolo[1,2- alpha ][1,4]diazepine-10-carbonyl)-2-methylbenzylcarbamoyl]-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl}acetic acid ethyl ester | VANTIA LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-8063038-B2 | vasopressin V2 receptor agonists for treating nocturnal enuresis, nocturia, diabetes insipidus, urinary incontinence and bleeding disorders; {1-[4-(5H,11H-Benzo[e]pyrrolo[1,2- alpha ][1,4]diazepine-10-carbonyl)-2-methylbenzylcarbamoyl]-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl}acetic acid ethyl ester | VANTIA LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| EP-1778677-B1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | VANTIA LTD (GB) | 2010-02-03 | — | — | EP | disclosed |
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | FERRING B.V. | 2008-09-25 | — | — | US | disclosed |
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | FERRING B.V. | 2008-09-25 | — | — | US | disclosed |
| WO-2006018443-A1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | FERRING B.V. (NL) | 2006-02-23 | — | — | WO | disclosed |
| EP-0805813-B1 | TRICYCLIC VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID CO (US) | 2002-05-15 | — | — | EP | disclosed |
| US-5968930-A | FOR TREATMENT AND/OR PREVENTION OF HYPERTENSION, CARDIAC INSUFFICIENCY, CORONARY VASOSPASM, CARDIAC ISCHEMIA, RENAL VASOSPASM, LIVER CIRRHOSIS, CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME, BRAIN EDEMA, CEREBRAL ISCHEMIA | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5968937-A | FOR TREATMENT AND/OR PREVENTION OF HYPERTENSION, CARDIAC INSUFFICIENCY, CORONARY VASOSPASM, CARDIAC ISCHEMIA, RENAL VASOSPASM, LIVER CIRRHOSIS, CONGESTIVE HEART FAILURE, NEPHROTIC SYNDROME, BRAIN EDEMA, CEREBRAL ISCHEMIA | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0636625-B1 | Tricyclic diazepines vasopressin and oxytocin antagonists | AMERICAN CYANAMID CO (US) | 1999-01-27 | — | — | EP | disclosed |
| US-5624923-A | UROGENITAL AND CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| US-5612334-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5610156-A | USED IN TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1996022293-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022292-A1 | TRICYCLIC VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5536718-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
| US-5521173-A | TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| US-5516774-A | TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0636625-A2 | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | AVPR2, AVPR1A, AVPR1B | KDM4E 4120/4885HPGD 151/4885BRPF1 3297/4885 |
| US-20230372528-A1 | GLYCOCONJUGATES | CD22, SIGLEC7, CD47 | KDM4E 2462/4885HPGD 3288/4885BRPF1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.